-+ 0.00%
-+ 0.00%
-+ 0.00%

Tokyo Pharmaceutical announced that the key phase 3 clinical trial of urcosimod for the treatment of neurogenic corneal pain has completed the first patient enrollment.

Zhitongcaijing·10/06/2026 11:09:08
Listen to the news
Tokyo Pharmaceutical announced that the key phase 3 clinical trial of urcosimod for the treatment of neurogenic corneal pain has completed the first patient enrollment.